South Korean biopharma firms remained active participants in the recent J.P. Morgan Healthcare Conference in San Francisco, which came as the second Trump Administration assumed power in the US and amid simmering political uncertainties in their home market.
Bridge Biotherapeutics Confident In IPF Contender As It Seeks Global Partner
Big Pharma Licensing Talks Underway
The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.
